Synonym |
Thai / English name |
Part Used : ไม่ระบุActivity : CYP2C19 INHIBITIONSolvent/Active Compound : Decurin and decursinol angelateType of experiment : in vivoType of animal : mouseType of study : -N(Total) : -N(Treatment) : -Sex : -Age : -Route : Oral administrationDose/Conc.(herb) : 6 mg D/DA mixture (approximately 3.6 mg decurin (D) and 2.4 mg decursinol angelate (DA))Duration : 2 hour after 1-aminobenotriazole (ABT) administrationType of interaction : PharmacokineticsInteraction with drug : 1-aminobenzotriazoleDose/Conc.(drug) : 3 mgResult : PositiveRemark : With ABT pretreatment for 2 h prior to D/DA dosing, the plasma D level was increased by 32-and 26-fold at 1 and 2 hours, and DA level was increased by 30-fold at both time points. The prostate D content was increased by 61-fold at both time points and the DA content was increased by 18- and 48-fold at 1 and 2 hours. Whereas a reduction of the plasma DOH level and prostate DOH content was anticipated for the ABT-pretreated mice, their observed values were, on the contrary, increased at each time point by ABT by 1.5-2 folds. The results suggest profound interactions among CYP inhibitor drug and D/DA metabolism that could significantly after systemic and prostate deposition of D, DA, and DOH.
Part Used : ไม่ระบุActivity : EFFECTS ON PHARMACOKINETICSolvent/Active Compound : Decurin and decursinol angelateType of experiment : in vivoType of animal : mouseType of study : -N(Total) : -N(Treatment) : -Sex : -Age : -Route : Oral administrationDose/Conc.(herb) : 6 mg D/DA mixture (approximately 3.6 mg decurin (D) and 2.4 mg decursinol angelate (DA))Duration : 2 hour after 1-aminobenotriazole (ABT) administrationType of interaction : PharmacokineticsInteraction with drug : 1-aminobenzotriazoleDose/Conc.(drug) : 3 mgResult : PositiveRemark : With ABT pretreatment for 2 h prior to D/DA dosing, the plasma D level was increased by 32-and 26-fold at 1 and 2 hours, and DA level was increased by 30-fold at both time points. The prostate D content was increased by 61-fold at both time points and the DA content was increased by 18- and 48-fold at 1 and 2 hours. Whereas a reduction of the plasma DOH level and prostate DOH content was anticipated for the ABT-pretreated mice, their observed values were, on the contrary, increased at each time point by ABT by 1.5-2 folds. The results suggest profound interactions among CYP inhibitor drug and D/DA metabolism that could significantly after systemic and prostate deposition of D, DA, and DOH.
Part Used : ไม่ระบุActivity : DRUG INTERACTIONSolvent/Active Compound : Decurin and decursinol angelateType of experiment : in vivoType of animal : mouseType of study : -N(Total) : -N(Treatment) : -Sex : -Age : -Route : Oral administrationDose/Conc.(herb) : 6 mg D/DA mixture (approximately 3.6 mg decurin (D) and 2.4 mg decursinol angelate (DA))Duration : 2 hour after 1-aminobenotriazole (ABT) administrationType of interaction : PharmacokineticsInteraction with drug : 1-aminobenzotriazoleDose/Conc.(drug) : 3 mgResult : PositiveRemark : With ABT pretreatment for 2 h prior to D/DA dosing, the plasma D level was increased by 32-and 26-fold at 1 and 2 hours, and DA level was increased by 30-fold at both time points. The prostate D content was increased by 61-fold at both time points and the DA content was increased by 18- and 48-fold at 1 and 2 hours. Whereas a reduction of the plasma DOH level and prostate DOH content was anticipated for the ABT-pretreated mice, their observed values were, on the contrary, increased at each time point by ABT by 1.5-2 folds. The results suggest profound interactions among CYP inhibitor drug and D/DA metabolism that could significantly after systemic and prostate deposition of D, DA, and DOH.